CLARIVATE PLC recently released its 10-Q report, providing insights into its financial performance and operations. The company operates as an information services provider across the Americas, the Middle East, Africa, Europe, and the Asia Pacific, functioning through three segments: Academia & Government, Life Sciences & Healthcare, and Intellectual Property. The company offers a range of solutions and expertise to research institutions, libraries, and professional services organizations, focusing on scientific and academic research, data solutions, and intellectual property management.
In Item 2 of the report, Management’s Discussion and Analysis of Financial Condition and Results of Operations, CLARIVATE PLC describes itself as a leading global provider of transformative intelligence, supporting the entire innovation lifecycle. The company offers enriched data, insights & analytics, workflow solutions, and expert services to customers in the Academia & Government, Intellectual Property, and Life Sciences & Healthcare end markets. Key Performance Indicators used to evaluate the business include organic revenue growth, annualized contract value, annual renewal rates, Adjusted EBITDA, Adjusted EBITDA margin, and Free cash flow.
The report provides specific financial figures for the three months ended September 30, 2025, and the nine months ended September 30, 2025. Revenues for the three months ended September 30, 2025, were $623.1 million, showing a marginal increase of 0.1% compared to the same period in 2024. For the nine months ended September 30, 2025, revenues were $1,838.2 million, a decrease of 3% compared to the same period in 2024.
The report also details the breakdown of revenues by transaction type, segment, and geography. For instance, the A&G segment saw an increase in revenues primarily due to subscription growth driven by new sales, improved retention, and price increases. In contrast, the IP segment experienced a decrease in revenues primarily due to lower re-occurring and transactional volumes. Additionally, the report highlights the impact of product divestitures and wind-downs on the company's revenue performance.
Furthermore, the report discusses specific financial measures such as Adjusted EBITDA, Adjusted EBITDA margin, and Free cash flow. It provides insights into the factors affecting the comparability of results of operations between the periods presented, including the impact of product wind-downs, divestitures, and impairments.
The market has reacted to these announcements by moving the company's shares -1.62% to a price of $3.64. Check out the company's full 10-Q submission here.
